Display Settings:

Format

Send to:

Choose Destination
    Nucleic Acids Res. 2008 Dec;36(21):6752-66. Epub 2008 Oct 25.

    Hairpin ribozyme-antisense RNA constructs can act as molecular Lassos.

    Source

    SomaGenics, Inc, Santa Cruz, CA 95060, USA.

    Abstract

    We have developed a novel class of antisense agents, RNA Lassos, which are capable of binding to and circularizing around complementary target RNAs. The RNA Lasso consists of a fixed sequence derived from the hairpin ribozyme and an antisense segment whose size and sequence can be varied to base pair with accessible sites in the target RNA. The ribozyme catalyzes self-processing of the 5'- and 3'-ends of a transcribed Lasso precursor and ligates the processed ends to produce a circular RNA. The circular and linear forms of the self-processed Lasso coexist in an equilibrium that is dependent on both the Lasso sequence and the solution conditions. Lassos form strong, noncovalent complexes with linear target RNAs and form true topological linkages with circular targets. Lasso complexes with linear RNA targets were detected by denaturing gel electrophoresis and were found to be more stable than ordinary RNA duplexes. We show that expression of a fusion mRNA consisting of a sequence from the murine tumor necrosis factor-alpha (TNF-alpha) gene linked to luciferase reporter can be specifically and efficiently blocked by an anti-TNF Lasso. We also show in cell culture experiments that Lassos directed against Fas pre-mRNA were able to induce a change in alternative splicing patterns.

    PMID:
    18953032
    [PubMed - indexed for MEDLINE]
    PMCID: PMC2588507
    Free PMC Article

    Images from this publication.See all images (7) Free text

    Figure 1.
    Figure 6.
    Figure 4.
    Figure 2.
    Figure 3.
    Figure 5.
    Figure 7.

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk